Vitamin E for people with non-alcoholic fatty liver disease

Wen, Hong-Zhu; Deng, Hongyu; Yang, Lili; Li, Lujin; J, Lin; Zheng, Peiyong; Ji, Guang

doi:10.1002/14651858.cd015033

Cited by 1 publication

(2 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vitamin E at a dose of 800 IU daily has been associated with amelioration in steatosis and inflammation as well as a reduction in serum ALT levels. However, high doses of vitamin E have been alleged to be related to increased all-cause mortality in a minority of studies [97]. In addition, it is noteworthy that high doses of vitamin E have also been associated with an increased risk of bleeding, a point that should be of particular concern for patients with NAFLD and cirrhosis, while a plausible relationship between prostate cancer and high doses of vitamin E has been reported as well [97].…”

Section: Nafld Treatment Optionsmentioning

confidence: 99%

“…However, high doses of vitamin E have been alleged to be related to increased all-cause mortality in a minority of studies [97]. In addition, it is noteworthy that high doses of vitamin E have also been associated with an increased risk of bleeding, a point that should be of particular concern for patients with NAFLD and cirrhosis, while a plausible relationship between prostate cancer and high doses of vitamin E has been reported as well [97]. Nevertheless, the impact of confounding factors, such as the concurrent use of other nutraceuticals, could account for these discrepancies among various studies [1].…”

Section: Nafld Treatment Optionsmentioning

confidence: 99%

See 1 more Smart Citation

NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics

Kounatidis,

Vallianou,

Geladari

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a major public health issue worldwide. It is the most common liver disease in Western countries, andits global prevalence is estimated to be up to 35%. However, its diagnosis may be elusive, because liver biopsy is relatively rarely performed and usually only in advanced stages of the disease. Therefore, several non-invasive scores may be applied to more easily diagnose and monitor NAFLD. In this review, we discuss the various biomarkers and imaging scores that could be useful in diagnosing and managing NAFLD. Despite the fact that general measures, such as abstinence from alcohol and modulation of other cardiovascular disease risk factors, should be applied, the mainstay of prevention and management is weight loss. Bariatric surgery may be suggested as a means to confront NAFLD. In addition, pharmacological treatment with GLP-1 analogues or the GIP agonist tirzepatide may be advisable. In this review, we focus on the utility of GLP-1 analogues and GIP agonists in lowering body weight, their pharmaceutical potential, and their safety profile, as already evidenced inanimal and human studies. We also elaborate on other options, such as the use of vitamin E, probiotics, especially next-generation probiotics, and prebiotics in this context. Finally, we explore future perspectives regarding the administration of GLP-1 analogues, GIP agonists, and probiotics/prebiotics as a means to prevent and combat NAFLD. The newest drugs pegozafermin and resmetiron, which seem to be very promising, arealso discussed.

show abstract

Section: Nafld Treatment Optionsmentioning

confidence: 99%